NEW YORK, Feb 15 – With scores of businesses looking to develop protein chips, it would seem a company with years of experience mass-producing microarrays might have a leg up on the competition. 

But Affymetrix, maker of the widely used GeneChip DNA microarrays, has no immediate plans to invest in protein chip research. “It’s just too far in the future,” a spokeswoman said.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.